CSF proteome profiling reveals biomarkers to discriminate dementia with Lewy bodies from Alzheimer´s disease

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: 1 Online-Ressource.

Language: Englisch

Bibliographic citation: CSF proteome profiling reveals biomarkers to discriminate dementia with Lewy bodies from Alzheimer´s disease ; volume:14 ; number:1 ; day:13 ; month:9 ; year:2023 ; pages:1-14 ; date:12.2023
Nature Communications ; 14, Heft 1 (13.9.2023), 1-14, 12.2023

Creator: Campo, Marta del
Vermunt, Lisa
Peeters, Carel F. W.
Sieben, Anne
Hok-A-Hin, Yanaika S.
Lleó, Alberto
Alcolea, Daniel
Nee, Mirrelijn van
Engelborghs, Sebastiaan
Alphen, Juliette L. van
Arezoumandan, Sanaz
Chen-Plotkin, Alice
Irwin, David J.
Flier, Wiesje M. van der
Lemstra, Afina W.
Teunissen, Charlotte E.

Contributor: SpringerLink (Online service)

DOI: 10.1038/s41467-023-41122-y

URN: urn:nbn:de:101:1-2024020210530681951559

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:33 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Campo, Marta del
Vermunt, Lisa
Peeters, Carel F. W.
Sieben, Anne
Hok-A-Hin, Yanaika S.
Lleó, Alberto
Alcolea, Daniel
Nee, Mirrelijn van
Engelborghs, Sebastiaan
Alphen, Juliette L. van
Arezoumandan, Sanaz
Chen-Plotkin, Alice
Irwin, David J.
Flier, Wiesje M. van der
Lemstra, Afina W.
Teunissen, Charlotte E.
SpringerLink (Online service)

Other Objects (12)

CSF markers of neurodegeneration Alzheimer’s and Lewy body pathology in isolated REM sleep behavior disorder

Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer’s disease core biomarkers in Lewy body disorders and Alzheimer’s dementia

CSF Presenilin-1 complexes are increased in Alzheimer’s disease

Levels of ADAM10 are reduced in Alzheimer’s disease CSF

Alzheimer’s disease CSF biomarkers: clinical indications and rational use

Retinal pathological features and proteome signatures of Alzheimer’s disease

Decreased CSF clearance and increased brain amyloid in Alzheimer’s disease

Heparin-enriched plasma proteome is significantly altered in Alzheimer’s disease

Dynamic changes of CSF clusterin levels across the Alzheimer’s disease continuum

Disease staging of Alzheimer’s disease using a CSF-based biomarker model

CSF p-tau205: a biomarker of tau pathology in Alzheimer’s disease

CSF level of β-amyloid peptide predicts mortality in Alzheimer’s disease

CSF markers of neurodegeneration Alzheimer’s and Lewy body pathology in isolated REM sleep behavior disorder

Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer’s disease core biomarkers in Lewy body disorders and Alzheimer’s dementia

CSF Presenilin-1 complexes are increased in Alzheimer’s disease

Levels of ADAM10 are reduced in Alzheimer’s disease CSF

Alzheimer’s disease CSF biomarkers: clinical indications and rational use

Retinal pathological features and proteome signatures of Alzheimer’s disease

Decreased CSF clearance and increased brain amyloid in Alzheimer’s disease

Heparin-enriched plasma proteome is significantly altered in Alzheimer’s disease

Dynamic changes of CSF clusterin levels across the Alzheimer’s disease continuum

Disease staging of Alzheimer’s disease using a CSF-based biomarker model

CSF p-tau205: a biomarker of tau pathology in Alzheimer’s disease

CSF level of β-amyloid peptide predicts mortality in Alzheimer’s disease

CSF markers of neurodegeneration Alzheimer’s and Lewy body pathology in isolated REM sleep behavior disorder

Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer’s disease core biomarkers in Lewy body disorders and Alzheimer’s dementia

CSF Presenilin-1 complexes are increased in Alzheimer’s disease

Levels of ADAM10 are reduced in Alzheimer’s disease CSF

Alzheimer’s disease CSF biomarkers: clinical indications and rational use

Retinal pathological features and proteome signatures of Alzheimer’s disease

Decreased CSF clearance and increased brain amyloid in Alzheimer’s disease

Heparin-enriched plasma proteome is significantly altered in Alzheimer’s disease

Dynamic changes of CSF clusterin levels across the Alzheimer’s disease continuum

Disease staging of Alzheimer’s disease using a CSF-based biomarker model

CSF p-tau205: a biomarker of tau pathology in Alzheimer’s disease

CSF level of β-amyloid peptide predicts mortality in Alzheimer’s disease

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read and agree to the privacy policy for the collection of personal data.*

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

CSF proteome profiling reveals biomarkers to discriminate dementia with Lewy bodies from Alzheimer´s disease

Show object

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

CSF markers of neurodegeneration Alzheimer’s and Lewy body pathology in isolated REM sleep behavior disorder

Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer’s disease core biomarkers in Lewy body disorders and Alzheimer’s dementia

CSF Presenilin-1 complexes are increased in Alzheimer’s disease

Levels of ADAM10 are reduced in Alzheimer’s disease CSF

Alzheimer’s disease CSF biomarkers: clinical indications and rational use

Retinal pathological features and proteome signatures of Alzheimer’s disease

Decreased CSF clearance and increased brain amyloid in Alzheimer’s disease

Heparin-enriched plasma proteome is significantly altered in Alzheimer’s disease

Dynamic changes of CSF clusterin levels across the Alzheimer’s disease continuum

Disease staging of Alzheimer’s disease using a CSF-based biomarker model

CSF p-tau205: a biomarker of tau pathology in Alzheimer’s disease

CSF level of β-amyloid peptide predicts mortality in Alzheimer’s disease

CSF markers of neurodegeneration Alzheimer’s and Lewy body pathology in isolated REM sleep behavior disorder

Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer’s disease core biomarkers in Lewy body disorders and Alzheimer’s dementia

CSF Presenilin-1 complexes are increased in Alzheimer’s disease

Levels of ADAM10 are reduced in Alzheimer’s disease CSF

Alzheimer’s disease CSF biomarkers: clinical indications and rational use

Retinal pathological features and proteome signatures of Alzheimer’s disease

Decreased CSF clearance and increased brain amyloid in Alzheimer’s disease

Heparin-enriched plasma proteome is significantly altered in Alzheimer’s disease

Dynamic changes of CSF clusterin levels across the Alzheimer’s disease continuum

Disease staging of Alzheimer’s disease using a CSF-based biomarker model

CSF p-tau205: a biomarker of tau pathology in Alzheimer’s disease

CSF level of β-amyloid peptide predicts mortality in Alzheimer’s disease

CSF markers of neurodegeneration Alzheimer’s and Lewy body pathology in isolated REM sleep behavior disorder

Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer’s disease core biomarkers in Lewy body disorders and Alzheimer’s dementia

CSF Presenilin-1 complexes are increased in Alzheimer’s disease

Levels of ADAM10 are reduced in Alzheimer’s disease CSF

Alzheimer’s disease CSF biomarkers: clinical indications and rational use

Retinal pathological features and proteome signatures of Alzheimer’s disease

Decreased CSF clearance and increased brain amyloid in Alzheimer’s disease

Heparin-enriched plasma proteome is significantly altered in Alzheimer’s disease

Dynamic changes of CSF clusterin levels across the Alzheimer’s disease continuum

Disease staging of Alzheimer’s disease using a CSF-based biomarker model

CSF p-tau205: a biomarker of tau pathology in Alzheimer’s disease

CSF level of β-amyloid peptide predicts mortality in Alzheimer’s disease

Related objects

Reset password